Please assess the completion status of the following clinical trial:

Trial Title: Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR Mutation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent provided.~* Aged 18-75 years.~* Had completely resected pathological confirmed stage IIA-IIIA NSCLC.~* EGFR activating mutation in exon 19 or 21.~* Had completed four cycles of platinum-based adjuvant chemotherapy.~* Able to start the investigational therapy within 4 weeks after the completion of four cycles of adjuvant chemotherapy.~* ECOG performance status of 0-1.~* Had a life expectancy of 12 weeks or more.~* Adequate hematological function, adequate liver function and renal function.~* Able to comply with the required protocol and follow-up procedures, and able to receive oral medications.~* Female patients, except those who are postmenopausal or surgically sterilized, must have a negative pre-study serum or urine pregnancy test.~Exclusion Criteria:~* Had had previous chemotherapy besides four cycles of adjuvant chemotherapy, radiotherapy, or agents directed at the HER axis (e.g. erlotinib, gefitinib, cetuximab, trastuzumab).~* Had a history another malignancy in the last 5 years with the exception of cured basal cell carcinoma of the skin, cured in situ carcinoma of the uterine cervix and cured epithelial carcinoma of the bladder.~* Any evidence confirmed tumor recurrence before investigational therapy.~* Known severe hypersensitivity to icotinib or any of the excipients of this product.~* Evidence of clinically active interstitial lung disease.~* Eye inflammation not fully controlled or conditions predisposing the subject to this.~* Any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the previous 6 months, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease).~* Known human immunodeficiency virus (HIV) infection.~* Pregnancy or breast-feeding women.~* Ingredients mixed with small cell lung cancer patients.~* History of neurologic or psychiatric disorders.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 6-month icotinib (Type: EXPERIMENTAL): Icotinib 125 mg three times daily (375 mg per day) by mouth for 6 months
- 12-month icotinib (Type: EXPERIMENTAL): Icotinib 125 mg three times daily (375 mg per day) by mouth for 12 months
- Chemotherapy alone (Type: NO_INTERVENTION): No intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).